Quanterix Corp. QTRX

What this company does

The company sells its proprietary instruments and related consumables worldwide to research laboratories, contract research organizations, academic institutions, and bio-pharmaceutical companies. It also provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests, through its Accelerator Laboratory, a facility certified under the Clinical Laboratory Improvement Amendments of 1988 and located in Bedford, Massachusetts. The company's platforms have an installed base of over 2,500 instruments and citations in more than 6,200 scientific publications, including in neurology, oncology, immunology, and inflammation. As of December 31, 2025, the company had 450 full-time employees, of whom 382 were located in the United States and 68 in 14 foreign countries. Its Simoa detection technology enables customers to detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids, while its Spatial Biology platforms perform multiplexed biomarker analysis in tissue samples to examine localized cellular interactions. Recurring revenue on the Simoa platform comes from consumables used to run assays on its instruments and from its menu of Simoa digital biomarker assays. Its Spatial Biology platforms perform end-to-end spatial phenotyping, allowing researchers to analyze large numbers of protein biomarkers and cell types across intact tissue sections at single-cell resolution. The company was incorporated in Delaware in April 2007 under the name Digital Genomics, Inc., and changed its name to Quanterix Corporation in August 2007.

Written from the business description in QUANTERIX CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.